OTCQB:
PHRRF
CSE:
PHRM
SPONSORED

In the U.S., the Total Number of Parkinson’s Patients Has Soared About 35% In the Last Decade(1)

Now There’s Fear Those Numbers Could Double in the Next 25 Years(1)

With Nearly Half of Those Patients Likely to Develop Levodopa-Induced Dyskinesia(2), PharmaTher Holdings Ltd. (CSE:PHRM)(OTCQB:PHRRF) May Have a Groundbreaking Treatment

Press Release May 17, 2021

Revive Therapeutics Enters into Feasibility Agreement with LTS Lohmann to Develop Oral Psil-o-cybin Thin Film Strip

Health professionals have become increasingly alarmed about Parkinson’s disease.(1)

At the moment, about 10 million people struggle with it worldwide. Up to roughly 60,000 people are diagnosed with it in the U.S. alone every year.(3)

Worse, a Parkinson’s epidemic could be on the horizon, according to Dr. Ray Dorsey, a neurologist at the University of Rochester Medical Center, as quoted by The Guardian.(1)

“Parkinson’s is already the fastest-growing neurological disorder in the world; in the U.S., the number of people with Parkinson’s has increased 35% the last 10 years. We think over the next 25 years it will double,” he added.(1)

Of course, that’s the last thing any of us want to hear.

While there is no cure for Parkinson’s just yet, treatments such as L-dopa, or Levodopa can help control the symptoms, including stiffness, weakness, and rigidity.

Unfortunately, even long-term exposure to L-dopa can cause issues like dyskinesia. Dyskinesia symptoms can include rapid, involuntary, and uncontrollable movements.(4)

That’s in addition to the tremors that are typically associated with Parkinson’s.

Luckily, there may be a solution for levodopa-induced dyskinesia in Parkinson’s patients (LID-PD). In fact, one that could help control the symptoms even better.

Biotech disruptor PharmaTher Holdings Ltd. (CSE:PHRM)(OTCQB:PHRRF) just announced the successful completion of a Type B pre-Investigational New Dr-ug meeting with the U.S. FDA regarding its proposed Phase 2 clinical study for ket-am-ine in the treatment of LID-PD.

Better, the US FDA already confirmed that a 505(b)(2) regulatory pathway is acceptable, which greenlights the potential to accelerate the clinical development for dr-ug approval.(5)

The Top Reasons to Consider PharmaTher Holdings Ltd. (CSE:PHRM)(OTCQB:PHRRF) Right Now

  1. Highly focused on developing novel uses, formulations and delivery forms of psychedelic pharmaceuticals, such as ket-am-ine, for Parkinson’s disease Depression, Lou Gehrig’s disease and pain.
  2. There is no cure for Parkinson’s, and worse a Parkinson’s epidemic could be on the horizon, says Dr. Ray Dorsey, a neurologist at the University of Rochester Medical Center, as quoted by The Guardian.(1)
  3. PharmaTher Holdings Ltd. (CSE:PHRM)(OTCQB:PHRRF) may have a groundbreaking solution to treat levodopa-induced dyskinesia in Parkinson’s patients (LID-PD). The company announced the successful completion of a Type B pre-Investigational New Dr-ug meeting with the U.S. FDA regarding its proposed Phase 2 clinical study of ket-am-ine based LID-PD treatments.(5)
  4. While the Parkinson’s treatment story is undoubtedly impressive, the company is also helping to treat MDD, or Major Depressive Disorder. According to Global Data, this market could be worth $7.87 billion by 2029 from $3.97 billion in 2019.(7) KETABET has already been shown to enhance the antidepressant effect while having the potential to significantly reduce the known adverse side effects of ket-am-ine.(8)
  5. Through a proprietary microneedle patch, KETABET aims to empower patients to dose their medication remotely, safely, and conveniently rather than under supervision by a healthcare provider at a certified medical office.(8)
  6. PharmaTher entered into a sponsored research agreement with the Terasaki Institute to develop a novel microneedle patch. This patch aims to deliver psych-e-delic pharmaceuticals such as psi-lo-cybin, and many others, through microdosing for unmet medical needs.(9)
  7. The company most recently entered into an exclusive license agreement with The University of Kansas to develop and commercialize the intellectual property of ket-am-ine to treat amyotrophic lateral sclerosis.(10)
  8. Diamond in the rough clinical-stage Psych-e-delic Biotech with ultra-low valuation compared to its psych-e-delic peers.
  9. World-class management team, scientific and clinical advisors, R&D partnerships and robust patent portfolio of 17 granted patent and patent applications

PharmaTher Holdings Ltd. (CSE:PHRM)(OTCQB:PHRRF) Has Bullish Indicators

After bottoming out around seven cents in late 2020, the PHRM stock rallied to a peak of approximately 65 cents. This was good for an eye-popping return of roughly 829% over only a few weeks.

Granted, the stock did correct to about 20 cents. However, the stock may still have plenty of momentum. Especially as PHRM progresses its vision of developing novel uses and delivery forms of ket-am-ine towards US FDA approval for its treatment of Parkinson’s patients, depression, and Lou Gehrig’s disease (ALS).

Additionally, as seen in the above chart, the PRHM stock looks aggressively oversold based on its relative strength (RSI), MACD, and Williams’ %R.

Just Who is PharmaTher Holdings Ltd. (CSE:PHRM)(OTCQB:PHRRF)?

PharmaTher Holdings Ltd. (CSE:PHRM)(OTCQB:PHRRF) is a specialty psych-e-delic pharmaceutical company focused on the research, development and commercialization of ket-am-ine and novel microneedle patches for delivering psych-e-delics to treat neuropsychiatric, neurodegenerative and pain disorders.

Along the way, the company plans to:(6)

  • Pursue innovative psych-e-delics as a prescription for FDA approval
  • Advance clinical studies of novel uses, formulations and delivery forms of ket-am-ine for Parkinson’s disease, Depression, and Lou Gehrig’s disease.
  • Develop its proprietary Microneedle patch to deliver psych-e-delics most effectively.
  • Discover new uses of psych-e-delics with panaceAI dr-ug repurposing AI platform.

While the Parkinson’s treatment story is certainly impressive, the company is also helping to treat MDD, or Major Depressive Disorder. According to Global Data, this market could be worth $7.87 billion by 2029 from $3.97 billion in 2019.(7)

PharmaTher (CSE:PHRM)(OTCQB:PHRRF) is Targeting Nearly 300 Million People with MDD

Earlier this year, the company announced it entered into an Exclusive Worldwide License Agreement with the National Health Research Institutes to develop and commercialize a patented combination formulation of FDA-approved ket-am-ine and betaine, or KETABET. KETABET could potentially act as a next-generation ket-am-ine treatment for mental health, neurological, and pain disorders.(12)

KETABET has already been shown to enhance the antidepressant effect while having the potential to significantly reduce the known adverse side effects of ket-am-ine.

Plus, through a proprietary microneedle patch, KETABET aims to empower patients to dose their medication remotely, safely, and conveniently rather than under supervision by a healthcare provider at a certified medical office.

PharmaTher also plans to seek FDA approval to conduct a Phase II clinical study for KETABET. This study intends to target approximately 300+ million people suffering from major depressive disorder and roughly 100 million people worldwide resistant to available treatments.

Shareholders May Also Want to Pay Attention PharmaTher’s Novel Microneedle Delivery System

PharmaTher recently entered into a sponsored research agreement with the Terasaki Institute. Under this agreement, the company plans to develop a novel microneedle patch aiming to deliver psych-e-delic pharmaceuticals such as psi-lo-cybin, and many others, through microdosing for unmet medical needs.(9)

PharmaTher’s microneedle delivery technology, based on novel biocompatible and biodegradable gelatin methacryloyl material, was developed by members of the Khademhosseini Lab at UCLA and the Terasaki Institute. It continues to innovate and expand its capabilities.

The product and clinical development plan will seek to obtain FDA approval in delivering various psych-e-delics for various mental health, neurological, and pain disorders.

PharmaTher (CSE:PHRM)(OTCQB:PHRRF) Showing Promise in Treating Lou Gehrig’s Disease

There is no known cure for ALS, which affects about 50,000 people in the U.S. and Europe, with over 5,000 new cases diagnosed annually.(13)

Sadly, ALS is a progressive neuromuscular disease with a life expectancy of only 2 to 6 years after diagnosis. As ALS advances, upper and lower motor neurons die, causing the brain to lose its ability to control muscle movement.

PharmaTher is hoping it can help with the use of ket-am-ine.

The company recently entered into an exclusive license agreement with The University of Kansas. This collaboration intends to develop and commercialize the intellectual property of ket-am-ine for treating amyotrophic lateral sclerosis.

University of Kansas Medical Center inventors Dr. Richard J. Barohn, M.D., John A. Stanford, Ph.D., and Dr. Matthew Macaluso, D.O., have made the promising discovery of ket-am-ine’s potential as an effective ALS treatment. Preclinical research indicates that the administration of ket-am-ine preserves muscle function in advancing ALS and increases life expectancy when administered in the early stages of muscle decline.

Strong Leadership, Strong Results — PharmaTher Holdings Ltd. (CSE:PHRM)(OTCQB:PHRRF)

The PharmaTher team includes world-class strategic partners, advisors, and a strong leadership team with a proven track record of success in dr-ug development, business development, and capital markets. All with a common goal of advancing its clinical product pipeline ​with ket-am-ine and psi-lo-cybin in Parkinson’s disease, depression, traumatic brain injury, and stroke. The team includes:

Fabio Chianelli
​Chairman and Chief Executive Officer

Mr. Chianelli has over 15 years of experience with specialty life sciences companies. He was the Founder and President of Revive Therapeutics Ltd. between 2012 and 2019. From January 2000 to January 2012, Mr. Chianelli held senior roles in investor relations, business development, and marketing and sales with Generex Biotechnology Corporation. Mr. Chianelli received his Bachelor of Commerce from Ryerson University.

Carmelo Marrelli
​Chief Financial Officer

Mr. Marrelli holds a Bachelor of Commerce degree from the University of Toronto. He is qualified as a Chartered Accountant and as a Certified General Accountant in Canada. Since February 2009, Mr. Marrelli has been a principal of Marrelli Support Services Inc., a firm providing administration services to Canadian public companies. He was also a partner with Marrelli & Drake Corporate Services (formerly Duguay & Ringler Corporate Services).

Dr. Owen Van Cauwenberghe, PhD
​Research and Development

Owen Van Cauwenbergh is an established leader and innovator with over 19 years of experience in the pharmaceutical and biotechnology sectors. He has a wide range of industry expertise in brand and generic strategic definition, organizational design, product/analytical /formulation development, project management, product innovation, and commercialization.​ His background also includes the following: Founding Partner, President, and COO of Bio Therapeutic Molecules Inc., Adjunct Associate Professor in the Waterloo School of Pharmacy, President and Board Member at MedC Biopharma, Expert Advisory Board Member at MMGenetics, former Chief Research Officer at AgMedica Bioscience Inc., former Director at Accucaps Industries Ltd. and former Principal Research Scientist and Director at Eli Lilly Canada.

Dr. Joga Gobburu, PhD, MBA
​Clinical and Regulatory Advisor

Dr. Gobburu is a world-renowned scientific leader in quantitative disease models and their applications to decisions. He is best known for transforming the field of pharmacometrics into a decision-supporting science. His experience as a senior biomedical research scientist and Director of Pharmacometrics at the Food and Dr-ug Administration (FDA) gives him unique insight into the technical, regulatory, and decision-making aspects in all phases of dr-ug development. He obtained his BPharm and MSc in chemistry from the Birla Institute of Technology and Science, his Ph.D. in pharmaceutical sciences from North Dakota State University, and his MBA from Johns Hopkins University.

Dr. Maurizio Fava, MD
Scientific and Clinical Advisor (Depression)

Dr. Fava is a world leader in the field of depression. He has edited eight books and authored or co-authored more than 900 original articles published in medical journals with international circulation. These articles have been cited more than 85,000 times in the literature and with an index of over 140. Dr. Fava founded and was director of the Massachusetts General Hospital (MGH) Depression Clinical and Research Program from 1990 until 2014. Under Dr. Fava’s direction, the Depression Clinical and Research Program became one of the most highly regarded depression programs in the country and a model for academic programs that link, in a bi-directional fashion, clinical and research work. In 2007, he also founded and is now the executive director of the MGH Psychiatry Clinical Trials Network and Institute. He became the first academic CRO to specialize in the coordination of multi-center clinical trials in psychiatry. Dr. Fava has successfully obtained funding as principal or co-principal investigator from both the National Institutes of Health and other sources for a total of more than $120 million. Dr. Fava’s prominence in the field is reflected in his role as the co-principal investigator of STAR*D, the most extensive research study ever conducted in the area of depression, and of the RAPID Network, the NIMH-funded series of studies of novel, rapidly-acting antidepressant therapies. Dr. Fava has also developed a novel design with Dr. David Schoenfeld (with over five patents), the sequential parallel comparison design (SPCD), to address the problem of excessive placebo response in dr-ug and to markedly reduce sample size requirements for these trials. He is also the former President of the American Society of Clinical Psychopharmacology.

Dr. Robert Hauser, MD, MBA
​Scientific and Clinical Advisor (Parkinson’s disease)

Dr. Robert Hauser is a Professor of Neurology at the University of South Florida College of Medicine in Tampa, Florida. He serves as Director of the USF Parkinson’s Disease and Movement Disorders Center, a Parkinson Foundation Center of Excellence. Dr. Hauser earned a medical degree from Temple University School of Medicine in Philadelphia, Pennsylvania, and completed neurology training at the Eastern Virginia Graduate School of Medicine in Norfolk, Virginia. Dr. Hauser completed a fellowship in Movement Disorders at the University of South Florida and became Center Director in 1994. Dr. Hauser has authored or co-authored more than 300 peer-reviewed publications and is one of the world’s most cited Parkinson’s Disease investigators.

Dr. Alberto Espay, MD
Scientific and Clinical Advisor (Parkinson’s disease)

Dr. Alberto Espay, MD, is professor and endowed chair of the University of Cincinnati James J. and Joan A. Gardner Family Center for Parkinson’s Disease and Movement Disorders. He trained in neurology at Indiana University and in clinical and electrophysiology of movement disorders at the University of Toronto. At the University of Toronto, he obtained a master’s degree in clinical epidemiology and healthcare research. A prolific researcher and author, Dr. Espay has published more than 250 peer-reviewed research articles, 25 book chapters, and seven books. His most recent is the first targeting the general public, Brain Fables. Dr. Espay has served as chair of the Movement Disorders Section of the American Academy of Neurology; associate editor of Movement Disorders, the official journal of the International Parkinson and Movement Disorder Society (MDS); and in the executive committee of the Parkinson Study Group. He currently serves as chair of the MDS Technology Task Force and secretary of the Pan-American Section of the MDS. Dr. Espay is also an honorary member of the Mexican Academy of Neurology.

Dr. Beverly J. Incledon – Director

Dr. Incledon is the Executive Vice President, Research & Development of Ironshore Pharmaceuticals & Development, Inc. Ironshore Pharmaceuticals & Development, Inc is a wholly-owned subsidiary of Toronto-based Highland Therapeutics Inc. Dr. Incledon has over 20 years of pharmaceutical industry experience encompassing dr-ug discovery, product development, pre-approval inspections, development quality, project management, method/technology transfer, process improvement, manufacturing troubleshooting, new development facility start-up, and research on novel dr-ug delivery technology. Dr. Incledon was a Post-Doctoral Fellow at Cornell University and obtained his Ph.D. degree in Biophysics and Bachelor of Science (Honors) in Applied Biochemistry with a Minor in Biomedical Technology from the University of Guelph.

Christian Scovenna – Director

Mr. Scovenna is a highly experienced C-Suite Executive with over 13 years of capital market experience working with both private and public microcap companies in Canada. He has held numerous directorships with publicly traded resource, pharmaceutical, and green leaf companies and has experience structuring deals and acquisitions and raising capital. In his previous engagement with Mojave Jane Brands Inc. (formerly High Hampton Holdings Corp.), he was instrumental in building the company as one of the original founders and was a vital member of the management team as interim CEO and Senior VP Corporate Finance while also serving on the board as a director. Mr. Scovenna currently serves as Director for Revive Therapeutics, Pasofino Gold Limited (formerly Enforcer Gold Corp.), and Tevano Payment Systems as VP Of Corporate Development.

Carlo Sansalone – Director

Mr. Sansalone is President at Sanscon Construction Ltd. He is on the Board of Directors at Revive Therapeutics Ltd. Mr. Sansalone received his undergraduate degree from Ryerson University.

The Top Reasons to Consider PharmaTher Holdings Ltd. (CSE:PHRM)(OTCQB:PHRRF) Right Now

  1. Highly focused on developing novel uses, formulations and delivery forms of psychedelic pharmaceuticals, such as ket-am-ine, for Parkinson’s disease Depression, Lou Gehrig’s disease and pain.
  2. There is no cure for Parkinson’s, and worse a Parkinson’s epidemic could be on the horizon, says Dr. Ray Dorsey, a neurologist at the University of Rochester Medical Center, as quoted by The Guardian.(1)
  3. PharmaTher Holdings Ltd. (CSE:PHRM)(OTCQB:PHRRF) may have a groundbreaking solution to treat levodopa-induced dyskinesia in Parkinson’s patients (LID-PD). The company announced the successful completion of a Type B pre-Investigational New Dr-ug meeting with the U.S. FDA regarding its proposed Phase 2 clinical study of ket-am-ine based LID-PD treatments.(5)
  4. While the Parkinson’s treatment story is undoubtedly impressive, the company is also helping to treat MDD, or Major Depressive Disorder. According to Global Data, this market could be worth $7.87 billion by 2029 from $3.97 billion in 2019.(7) KETABET has already been shown to enhance the antidepressant effect while having the potential to significantly reduce the known adverse side effects of ket-am-ine.(8)
  5. Through a proprietary microneedle patch, KETABET aims to empower patients to dose their medication remotely, safely, and conveniently rather than under supervision by a healthcare provider at a certified medical office.(8)
  6. PharmaTher entered into a sponsored research agreement with the Terasaki Institute to develop a novel microneedle patch. This patch aims to deliver psych-e-delic pharmaceuticals such as psi-lo-cybin, and many others, through microdosing for unmet medical needs.(9)
  7. The company most recently entered into an exclusive license agreement with The University of Kansas to develop and commercialize the intellectual property of ket-am-ine to treat amyotrophic lateral sclerosis.(10)
  8. Diamond in the rough clinical-stage Psych-e-delic Biotech with ultra-low valuation compared to its psych-e-delic peers.
  9. World-class management team, scientific and clinical advisors, R&D partnerships and robust patent portfolio of 17 granted patent and patent applications
Source 1: https://www.theguardian.com/commentisfree/2021/apr/07/rates-of-parkinsons-disease-are-exploding-a-common-chemical-may-be-to-blame
Source 2: https://bit.ly/31V8jnl
Source 3: https://www.parkinson.org/Understanding-Parkinsons/Statistics
Source 4: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2600052/
Source 5: https://bit.ly/3fPNbHa
Source 6: https://www.pharmather.com/uploads/1/2/5/8/125844350/deck_-_phrm_-_1020201.pdf
Source 7: https://www.expresspharma.in/market-pharma/novel-pipeline-agents-to-drive-global-major-depressive-disorder-market-globaldata/
Source 8: https://prn.to/39UdHvc
Source 9: https://on.mktw.net/3uxgF0z
Source 10: https://money.yahoo.com/pharmather-expands-neuromuscular-diseases-exclusive-120000227.html
Source 11: https://stockcharts.com/h-sc/ui?s=PHRM.CA
Source 12: https://bit.ly/3rVjQ0k
Source 13: https://bit.ly/3fQDzvF

Legal Disclaimer


This website / media webpage is owned, operated and edited by TD Media LLC. Any wording found on this website / media webpage or disclaimer referencing to “I” or “we” or “our” or “TD Media” refers to TD Media LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to market and promote small public companies. By reading our website / media webpage you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our website / media webpage.We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website / media webpage are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our website / media webpage may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. TD Media business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our Websites, Email, SMS, Push Notifications, Influencers, Social Media Postings, Ticker Tags, Press Releases, Online Interviews, Podcasts, Videos, Audio Ads, Banner Ads, Native Ads, Responsive Ads. This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, TD Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.

INFLUENCER COMPENSATION

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 04/19/2021 and ending on 04/21/2021 to publicly disseminate information about (PHRRF:US) (PHRM:CA) via digital communications. We have paid this Influencer five hundred dollars USD.

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 04/19/2021 and ending on 04/19/2021 to publicly disseminate information about (PHRRF:US) (PHRM:CA) via digital communications. We have paid this Influencer one thousand dollars USD.

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 04/19/2021 and ending on 04/19/2021 to publicly disseminate information about (PHRRF:US) (PHRM:CA) via digital communications. We have paid this Influencer one thousand five hundred forty five dollars USD.

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 04/19/2021 and ending on 04/19/2021 to publicly disseminate information about (PHRRF:US) (PHRM:CA) via digital communications. We have paid this Influencer one thousand dollars USD.

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 04/20/2021 and ending on 04/22/2021 to publicly disseminate information about (PHRRF:US) (PHRM:CA) via digital communications. We have paid this Influencer one hundred ninety five dollars USD.

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 04/20/2021 and ending on 04/22/2021 to publicly disseminate information about (PHRRF:US) (PHRM:CA) via digital communications. We have paid this Influencer three hundred fifty dollars USD.

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 04/20/2021 and ending on 04/20/2021 to publicly disseminate information about (PHRRF:US) (PHRM:CA) via digital communications. We have paid this Influencer one thousand five hundred dollars USD.

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 04/20/2021 and ending on 04/22/2021 to publicly disseminate information about (PHRRF:US) (PHRM:CA) via digital communications. We have paid this Influencer eight hundred dollars USD.

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 04/22/2021 and ending on 04/22/2021 to publicly disseminate information about (PHRRF:US) (PHRM:CA) via digital communications. We have paid this Influencer one thousand dollars USD.

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 04/22/2021 and ending on 04/22/2021 to publicly disseminate information about (PHRRF:US) (PHRM:CA) via digital communications. We have paid this Influencer four hundred dollars USD.

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 04/24/2021 and ending on 04/26/2021 to publicly disseminate information about (PHRRF:US) (PHRM:CA) via digital communications. We have paid this Influencer one hundred ten dollars USD.

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 04/26/2021 and ending on 04/28/2021 to publicly disseminate information about (PHRRF:US) (PHRM:CA) via digital communications. We have paid this Influencer three hundred dollars USD.

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 04/28/2021 and ending on 04/28/2021 to publicly disseminate information about (PHRRF:US) (PHRM:CA) via digital communications. We have paid this Influencer three hundred dollars USD.

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 05/04/2021 and ending on 05/04/2021 to publicly disseminate information about (PHRRF:US) (PHRM:CA) via digital communications. We have paid this Influencer eight hundred fifty dollars USD.

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 05/17/2021 and ending on 05/17/2021 to publicly disseminate information about (PHRRF:US) (PHRM:CA) via digital communications. We have paid this Influencer one thousand dollars USD.

COMPENSATION

Pursuant to an agreement between TD Media LLC and PharmaTher Inc, TD Media LLC has been hired for a period beginning on 02/25/2021 and ending on 02/25/2021 to publicly disseminate information about (PHRRF:US) (PHRM:CA) via digital communications. We have been paid seven thousand dollars USD via bank wire transfer.

Pursuant to an agreement between TD Media LLC and PharmaTher Inc, TD Media LLC has been hired for a period beginning on 04/19/2021 and ending on 05/19/2021 to publicly disseminate information about (PHRRF:US) (PHRM:CA) via digital communications. We have been paid an additional one hundred thousand dollars USD via bank wire transfer. We own zero shares of (PHRRF:US) (PHRM:CA). To date we have been paid one hundred seven thousand dollars USD via bank wire transfer. To disseminate information about (PHRRF:US) (PHRM:CA) via digital communications.

Company Contact

Address: 82 Richmond Street East, Toronto, Ontario  Canada M5C 1P1
Phone: 1-888-846-3171
Website: www.pharmather.com

What They Do

PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) is a specialty psych-e-delic pharmaceutical company focused on the research, development and commercialization of ket-am-ine and novel microneedle patches for delivering psych-e-delics to treat neuropsychiatric, neurodegenerative and pain disorders.